Abstract
Tetherin is a type II membrane protein that bears a N-terminal transmembrane domain, an extracellular coiledcoil structure and a C-terminal GPI anchor. This unique topology allows tetherin to block the release of a wide range of enveloped viruses from the cell surface. In order to overcome this host restriction, viruses have evolved various counter measures. In the case of human immunodeficiency virus type 1 (HIV-1), the viral protein U (Vpu) is able to downmodulate cell surface tetherin, thus removing tetherin molecules from the site of virus budding. This activity of Vpu depends on its direct interaction with tetherin. In this review, we summarize the known molecular details of the interaction between Vpu and tetherin, and also discuss how tetherin is targeted by other viral antagonists. Following our summary, it is evident that each of the intracellular, transmembrane and extracellular domains of tetherin can become the target of viral antagonists for counteraction.
Keywords: HIV, Vpu, tetherin, Nef, Envelope, CD4, transmembrane domain, NMR, TM, residues
Current HIV Research
Title:Transmembrane Interactions of HIV-1 Vpu and Tetherin
Volume: 10 Issue: 4
Author(s): Fei Guo and Chen Liang
Affiliation:
Keywords: HIV, Vpu, tetherin, Nef, Envelope, CD4, transmembrane domain, NMR, TM, residues
Abstract: Tetherin is a type II membrane protein that bears a N-terminal transmembrane domain, an extracellular coiledcoil structure and a C-terminal GPI anchor. This unique topology allows tetherin to block the release of a wide range of enveloped viruses from the cell surface. In order to overcome this host restriction, viruses have evolved various counter measures. In the case of human immunodeficiency virus type 1 (HIV-1), the viral protein U (Vpu) is able to downmodulate cell surface tetherin, thus removing tetherin molecules from the site of virus budding. This activity of Vpu depends on its direct interaction with tetherin. In this review, we summarize the known molecular details of the interaction between Vpu and tetherin, and also discuss how tetherin is targeted by other viral antagonists. Following our summary, it is evident that each of the intracellular, transmembrane and extracellular domains of tetherin can become the target of viral antagonists for counteraction.
Export Options
About this article
Cite this article as:
Guo Fei and Liang Chen, Transmembrane Interactions of HIV-1 Vpu and Tetherin, Current HIV Research 2012; 10 (4) . https://dx.doi.org/10.2174/157016212800792450
DOI https://dx.doi.org/10.2174/157016212800792450 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
IP6 in Cancer Therapy: Past, Present and Future
Current Cancer Therapy Reviews Patent Selections
Recent Patents on Biomarkers NCRNA Combined Therapy as Future Treatment Option for Cancer
Current Pharmaceutical Design Recent Advances in Thymidine Kinase 2 (TK2) Inhibitors and New Perspectives for Potential Applications
Current Pharmaceutical Design Cancer Therapy By Targeting Hypoxia-Inducible Factor-1
Current Cancer Drug Targets Tyrosine Kinase Inhibitors
Current Cancer Drug Targets Applications of Polymeric Nanocapsules in Field of Drug Delivery Systems
Current Drug Discovery Technologies Immunossupressant and Organ Transplantation: Immunophilins Targeting Agent and Alternative Therapies
Current Medicinal Chemistry Exploring the Role of Phytochemicals as Potent Natural Photosensitizers in Photodynamic Therapy
Anti-Cancer Agents in Medicinal Chemistry Engineering Chemokines to Develop Optimized HIV Inhibitors
Current Protein & Peptide Science Glucans as Biological Response Modifiers
Endocrine, Metabolic & Immune Disorders - Drug Targets Cyclin-Dependent Kinase 4/6 (Cdk4/6) Inhibitors: Perspectives in Cancer Therapy and Imaging
Mini-Reviews in Medicinal Chemistry The p53-Mdm2 Pathway: Targets for the Development of New Anticancer Therapeutics
Mini-Reviews in Medicinal Chemistry Anti-Neoplastic Activity of 1,3-Diaza-2-Functionalized-Adamantan-6-One Compounds Against Melanoma Cells
Medicinal Chemistry Vertebral Lesions from AIDS-Related Kaposi's Sarcoma
Current HIV Research PSMA7, A Potential Biomarker of Diseases
Protein & Peptide Letters Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic Diseases
Current Neuropharmacology Versatility of Cancer Associated Fibroblasts: Commendable Targets for Anti-tumor Therapy
Current Drug Targets Nanotechnology for Delivery of Drugs and Biomedical Applications
Current Clinical Pharmacology MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance
Current Drug Targets